Melanoma Clinical Trials in Minneapolis

Showing 81-100 of 109 trials

Aldesleukin With or Without Vaccine Therapy in Treating Patients With Stage IV Melanoma

NCT00726739

RATIONALE: Aldesleukin may stimulate the white blood cells to kill tumor cells. Vaccines may help the body build an effective immune response to kill tumor cells. Giving aldesleukin together with vaccine therapy may kill more tumor cells. It is not yet known whether aldesleukin is more effective with or without vaccine therapy in treating melanoma. PURPOSE: This randomized phase II trial is studying how well aldesleukin works when given with or without vaccine therapy in treating patients with stage IV melanoma.

Stage IV Melanoma

Masonic Cancer Center, University of Minnesota21 participantsStarted Jun 2008

Minneapolis, Minnesota, United States

COMPLETEDPHASE2< 1 mile

Temozolomide and Everolimus in Treating Patients With Stage IV Melanoma That Cannot be Removed by Surgery

NCT00521001

RATIONALE: Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Everolimus may stop the growth of tumor cells by blocking blood flow to the tumor and by blocking some of the enzymes needed for cell growth. Giving everolimus together with temozolomide may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving everolimus together with temozolomide works in treating patients with stage IV melanoma that cannot be removed by surgery

Melanoma (Skin)

Alliance for Clinical Trials in Oncology49 participantsStarted Jan 2008

Aurora, Colorado, United States • Boulder, Colorado, United States • Colorado Springs, Colorado, United States +195 more locations

Aldesleukin With or Without Vaccine Therapy in Treating Patients With Stage IV Melanoma

Temozolomide and Everolimus in Treating Patients With Stage IV Melanoma That Cannot be Removed by Surgery

Melanoma Trials in Other Cities

Temozolomide and Radiation Therapy in Treating Patients With Stage IV Malignant Melanoma With Measurable and Unresectable Cancer of the Central Nervous System

Inhaled Sargramostim in Treating Patients With Melanoma Metastatic to the Lung

Vaccine Therapy Compared With Interferon Alfa in Treating Patients With Stage III Melanoma

STA-4783/Paclitaxel or Paclitaxel Alone in Melanoma

A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers

Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Stage IV Melanoma

CAVATAK in Patients With Stage IIIc or IV Malignant Melanoma to Extend Dosing to 48 Weeks (VLA-008 CALM Ext)

Phase II, 2nd Line Melanoma - RAND Monotherapy

Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain Metastases

A Study of Intratumoral CAVATAK™ in Patients With Stage IIIc and Stage IV Malignant Melanoma (VLA-007 CALM )

Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone

Safety, Tolerability and Efficacy Study of the Monoclonal Antibody, CT-011, in Patients With Metastatic Melanoma

Study to Compare the Effect of Ipilimumab Retreatment With That of Chemotherapy in Advanced Melanoma

Phase 1 Study of GRN-1201 in HLA-A*02 Subjects With Resected Melanoma

A Study of IMC-1121B (Ramucirumab) With or Without Dacarbazine in Metastatic Malignant Melanoma

A Study of Recombinant Vaccinia Virus to Treat Malignant Melanoma

Phase II Study to Determine Predictive Markers of Response to BMS-734016 (MDX-010)

SciBase International Melanoma Pivotal Study

Other Conditions in Minneapolis